UroGen Wins First FDA Approval With Jelmyto For Urothelial Cancer

Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology. 

UroGen Pharma Ltd. is launching its first commercial drug following the US Food and Drug Administration approval of Jelmyto (mitomycin) for adults with low-grade upper tract urothelial cancer (LG UTUC). The company announced the approval after market close on 15 April and said it will aim to launch the drug on 1 June despite the ongoing COVID-19 pandemic.

"None of us could have anticipated that we would be executing a launch in the middle of a pandemic," CEO...

More from New Products

Rhythm Gets US Decision Date For Hypothalamic Obesity Treatment

 

Already approved in two rare obesity conditions, Rhythm’s Imcivree looks on course to gain acquired hypothalamic obesity approval and reach blockbuster status.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By 

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Wegovy’s Win In MASH Gives Novo A Much-Needed Edge Over Lilly

 
• By 

Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By 

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By 

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.